About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
GALT - Galectin Therapeutic...| Previous Close | $2.23 | Open | $2.19 |
| Volume | 281.5K | Market Cap | 226.22M |
| Yield | Last Dividend |
| Galectin Therapeutics Inc. Recaps Result... | 12/04/20 |
| Chairman Dick Uihlein, CEO and President Joel Lewis, and Chief Medical Officer Pol Boudes Provide Corporate Highlights on Company???s Three Active Cli... | |
| Head to Head Contrast: BIOLINERX LTD/S (... | 10/22/20 |
| BIOLINERX LTD/S (NASDAQ:BLRX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will c... | |
| EmergingGrowth.com Reports on Why Galect... | 09/29/20 |
| The run up yesterday represents only a small fraction of the COVID-19 market and very little is priced into the equity at a $200 million market capita... | |
| Insider Buys Galectin Therapeutics Stock | 09/09/20 |
| Shares of Galectin Therapeutics Inc (NASDAQ:GALT) moved higher by 8.3% from the previous closing price. A Form 4 filing filed with the SEC on Wednesda... | |
| Galectin Therapeutics Reports Financial ... | 08/10/20 |
| NASH-RX Trial Continues to Enroll New Patients | |
| Galectin Therapeutics' Shares March High... | 05/22/20 |
| As of late, it has definitely been a great time to be an investor in Galectin Therapeutics. | |
| The Daily Biotech Pulse: LogicBio Slappe... | 02/11/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) ... | |
| The Daily Biotech Pulse: EyePoint In-Lic... | 02/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Ac... | |
| The Daily Biotech Pulse: Sanofi Reports ... | 01/30/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 29) ... | |
| The Daily Biotech Pulse: Novartis Earnin... | 01/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) ... | |
| The Daily Biotech Pulse: Correvio Faces ... | 12/11/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) ... | |
| Need To Know: Galectin Therapeutics, Inc... | 08/27/19 |
| We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On??? | |
| Galectin sets lower price in rights offe... | 05/24/19 |
| No summary available. | |
| Madrigal, Galmed, And Galectin In Phase ... | 05/22/19 |
| No summary available. | |
| Galectin Therapeutics: Primed For Takeof... | 05/15/19 |
| No summary available. | |
| Galectin Therapeutics misses by $0.06 | 05/10/19 |
| No summary available. | |
| ROAN, SOHU, CYOU and GDI among notable m... | 04/29/19 |
| No summary available. | |
| Galectin Therapeutics And Belapectin In ... | 04/11/19 |
| No summary available. | |
| NASH players in the red as EASL announce... | 04/11/19 |
| No summary available. | |
| Daily Insider Ratings Round Up 4/9/19 | 04/11/19 |
| No summary available. | |
| Galectin Therapeutics (GALT) Presents At... | 04/09/19 |
| No summary available. | |
| Galectin readies subscription rights off... | 04/08/19 |
| No summary available. | |
| Conatus flop fails to move NASH players | 03/22/19 |
| No summary available. | |
| Galectin files for subscription rights o... | 03/20/19 |
| No summary available. | |
| Galectin In NASH, And The Market Assessm... | 03/15/19 |
| No summary available. | |
| Conatus up 22% ahead of Emricasan data p... | 03/13/19 |
| No summary available. | |
| Galectin files for rights offering; shar... | 03/06/19 |
| No summary available. | |
| Galectin Therapeutics Likely To Apprecia... | 02/20/19 |
| No summary available. | |
| Intercept data stokes NASH players | 02/19/19 |
| No summary available. | |
| Piper likes OncoCyte in premarket analys... | 02/13/19 |
| No summary available. | |
| Date | 2020-11-09 (BMO) | Est. (EPS/Rev.) | ($0.14)/ 0 |
| Actual (EPS/Rev.) | $-0.10/ | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech and Biotech Catalysts | Michael | 43.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
